---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000054"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-07-09T21:10:23+00:00"
generated_at: "2026-07-09T21:12:04.594473+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Travere Therapeutics CAO Sandra Calvin to retire; John Torell to succeed

## Summary
- Sandra Calvin to retire as CAO/PAO after filing 10-K expected in February 2027.
- John Torell, current VP Controller, to be appointed CAO/PAO before retirement date.
- Torell joined Travere in 2021; previously VP Controller at Pacific Life and audit manager at Deloitte.
- Torell holds CFA and CPA designations; transition plan aims for orderly handover.

## SEC filing metadata
- accession: 0001438533-26-000054
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-07-09T21:10:23+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/0001438533-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/tvtx-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000054
- JSON: https://secwatch.observer/filing/0001438533-26-000054.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.